Stevanato Group Past Earnings Performance
Past criteria checks 1/6
Stevanato Group has been growing earnings at an average annual rate of 17%, while the Life Sciences industry saw earnings growing at 19.6% annually. Revenues have been growing at an average rate of 13.5% per year. Stevanato Group's return on equity is 10.2%, and it has net margins of 12.6%.
Key information
17.0%
Earnings growth rate
14.4%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 13.5% |
| Return on equity | 10.2% |
| Net Margin | 12.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Stevanato Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,083 | 136 | 113 | 37 |
| 31 Dec 23 | 1,085 | 146 | 114 | 36 |
| 30 Sep 23 | 1,057 | 149 | 116 | 36 |
| 30 Jun 23 | 1,031 | 147 | 117 | 35 |
| 31 Mar 23 | 1,010 | 143 | 117 | 35 |
| 31 Dec 22 | 984 | 143 | 112 | 34 |
| 30 Sep 22 | 924 | 139 | 100 | 33 |
| 30 Jun 22 | 893 | 122 | 95 | 33 |
| 31 Mar 22 | 863 | 125 | 86 | 31 |
| 31 Dec 21 | 844 | 134 | 83 | 30 |
| 30 Sep 21 | 818 | 123 | 82 | 25 |
| 30 Jun 21 | 761 | 121 | 79 | 22 |
| 31 Mar 21 | 718 | 108 | 79 | 19 |
| 31 Dec 20 | 662 | 79 | 79 | 17 |
| 31 Dec 19 | 537 | 39 | 77 | 8 |
Quality Earnings: 87N has a high level of non-cash earnings.
Growing Profit Margin: 87N's current net profit margins (12.6%) are lower than last year (14.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 87N's earnings have grown by 17% per year over the past 5 years.
Accelerating Growth: 87N's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 87N had negative earnings growth (-5%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.7%).
Return on Equity
High ROE: 87N's Return on Equity (10.2%) is considered low.